A randomized trial of patients with T2DM showed that ARBs were associated with significantly reduced urinary excretion of angiotensinogen in participants overall (−5.4% vs. −1.7% at week 24), and lower albuminuria in participants with high-normal albuminuria (–4.8% vs. −4.3% at week 24), compared with treatment with a direct renin inhibitor [53]. Here, REN is linked to type 2 diabetes mellitus.